Article

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.
Diabetes care (Impact Factor: 8.57). 09/2010; 33(9):2113-6. DOI: 10.2337/dc10-0357
Source: PubMed

ABSTRACT To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Post hoc analysis of over 2,000 metabolic syndrome patients administered either FA + low- or moderate-dose statin; FA alone; or low-, moderate-, or high-dose statin alone.
FA + low- or moderate-dose statin combination therapy reduced the presence of metabolic syndrome (35.7 or 35.9%, respectively) more than low-, moderate-, or high-dose statin monotherapy (15.5, 16.6, or 13.8%, respectively), mostly due to improvements in triglycerides and HDL cholesterol levels. Mean glucose levels slightly decreased with FA monotherapy, slightly increased with statin monotherapy, and were essentially unchanged with FA + statin. FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.
FA + statin in patients with mixed dyslipidemia reduces the prevalence of metabolic syndrome.

Download full-text

Full-text

Available from: Eli M Roth, Aug 15, 2015
0 Followers
 · 
134 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The theoretical opportunity of creating chaotic generators is also investigated experimentally on the basis of two or more coupled one-transistor generators in the microwave range. The paper reports the design of transistor microwave oscillators in which it is possible to control the frequency band and the spectral characteristic is smooth. We show that the use of two and three coupled transistor auto-oscillators allows us to create microwave chaotic wide-band generators.
    Microwave and Telecommunication Technology, 2004. CriMico 2004. 2004 14th International Crimean Conference on; 10/2004
  • Journal of Clinical Lipidology 11/2011; 5(6):424-33. DOI:10.1016/j.jacl.2011.09.006 · 3.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study is to compare the non-lipid effects of rosuvastatin-fenofibrate combination therapy with rosuvastatin monotherapy in high-risk Asian patients with mixed hyperlipidemia. A total of 236 patients were initially screened. After six weeks of diet and life style changes, 180 of these patients were randomly assigned to receive one of two regimens: rosuvastatin 10 mg plus fenofibrate 160 mg or rosuvastatin 10 mg. The primary outcome variables were the incidences of muscle or liver enzyme elevation. The patients were followed for 24 weeks during drug treatment and for an additional four weeks after drug discontinuation. The rates of the primary outcome variables were similar between the two groups (2.8% and 3.9% in the combination and the rosuvastatin groups, respectively, p=1.00). The combination group had more, but not significantly, common treatment-related adverse events (AEs) (13.3% and 5.6%, respectively) and drug discontinuation due to AEs (10.0% and 3.3%, respectively) than the rosouvastatin group. Combination therapy was associated with higher elevations in homocysteine, blood urea nitrogen, and serum creatinine, whereas elevation in alanine aminotransferase was greater in the rosuvastatin group. Leukocyte count and hemoglobin level decreased to a greater extent in the combination group. The combination group showed greater reductions in TG and elevation in HDL-cholesterol. In our study population, the rosuvastatin-fenofibrate combination resulted in comparable incidences of myo- or hepatotoxicity as rosuvastatin monotherapy. However, this combination may need to be used with caution in individuals with underlying pathologies such as renal dysfunction (NCT01414803).
    Atherosclerosis 03/2012; 221(1):169-75. DOI:10.1016/j.atherosclerosis.2011.12.042 · 3.97 Impact Factor
Show more